Procept BioRobotics touts early results from AquaBeam BPH waterjet ablation trial

Procept BioRobotics today released early results from a study of its AquaBeam waterjet ablation therapy system designed for the endoscopic resection of prostate tissue exploring its use in treating benign prostatic hyperplasia, touting that it already met its primary safety and efficacy endpoints. Results were presented at the American Urological Association’s annual meeting in San Francisco by study co-principal investigator Dr. Mihir Desai of the Keck School of Medicine of USC, the Redwood Shores, Calif.-based company said. The AquaBeam system uses a robotically controlled waterjet to ablate prostate tissue without needing heat, Procept said. The 101-patient trial sought to explore its ability to treat urinary symptoms due to BPH at 16 sites across the US and Canada. Data from the trial indicated that use of the AquaBeam system in men with prostate volumes between 80 mL and 150 mL resulted in significant improvements in both symptom scores and urinary flow rates while meeting its safety profile endpoints with statistical significance. “On the heels of the Water study, the results of the Water II study confirmed aquablation delivers predictable and reproducible results regardless of the size of the prostate. These results suggest that aquablation can be a minimally invasive, transurethral option for patients with larger prostates who would otherwise only be candidates for simple prostatectomy. The pooled analysis demonstrated that, despite the increased prostate...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Robotics Urology Procept BioRobotics Source Type: news